Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia A inhibitor mice

Frontiers in Immunology

Volumn 4, Issue JAN, 2014, Pages

  Liu, Chao Lien ^a,b   Ye, Peiqing ^a   Lin, Jacqueline ^a   Butts, Chérie L ^c   Miao, Carol H ^a,d  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c BIOGEN   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD20; B cell depletion; Factor VIII; Hemophilia; Immunomodulation; Tolerance induction

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CD20 ANTIBODY; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA; HUMORAL IMMUNE DEFICIENCY; IMMOBILIZED CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN;

EID: 84987781475     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00502     Document Type: Article

References (51)

1. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost (2004) 2(7):1047-54. doi: 10.1046/j.1538-7836.2004.00710.x
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 339(8793):594-8. doi:10.1016/0140-6736(92)90874-3
3. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol (2002) 29(1 Suppl 2):105-12. doi:10.1053/sonc.2002.30145
4. Bour-Jordan H, Bluestone JA. B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 117(12):3642-5. doi:10.1172/JCI34236
5. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol (2003) 14(4):520-35. doi:10.1093/annonc/mdg175
6. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs (2003) 63(8):803-43. doi:10.2165/00003495-200363080-00005
7. Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One (2013) 8(2):e54712. doi:10.1371/journal.pone.0054712
8. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol (2006) 6(5):394-403. doi:10.1038/nri1838
9. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun (2012) 39(1-2):103-11. doi:10.1016/j.jaut.2012.01.009
10. Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ (2013) 1:e31. doi:10.7717/peerj.31
11. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 2(6):676-90.
12. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood (2010) 115(25):5191-201. doi:10.1182/blood-2010-01-263533
13. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol (2010) 28(21):3525-30. doi:10.1200/JCO.2010.27.9836
14. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 104(9):2635-42. doi:10.1182/blood-2004-03-1110
15. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood (2011) 117(7):2223-6. doi:10.1182/blood-2010-06-293324
16. Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, et al. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One (2012) 7(5):e37671. doi:10.1371/journal.pone.0037671
17. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of isletallografts without immunosuppression. J Exp Med (2009) 206(4):751-60. doi:10.1084/jem.20082824
18. Wilson MS, Pesce JT, Ramalingam TR, Thompson RW, Cheever A, Wynn TA. Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol (2008) 181(10):6942-54.
19. Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi FD. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol (2010) 40(6):1577-89. doi:10.1002/eji.200939792
20. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation (2001) 72(7):1181-93. doi:10.1097/00007890-200110150-00001
21. 25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation. Cell Immunol (2010) 264(2):111-3. doi:10.1016/j.cellimm.2010.05.014
22. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 4(6):e5994. doi:10.1371/journal.pone.0005994
23. 3+ regulatory T-cells. Diabetes (2008) 57(9):2341-7. doi:10.2337/db08-0138
24. Liu CL, Ye P, Yen BC, Miao CH. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol Ther (2011) 19(8):1511-20. doi:10.1038/mt.2011.61
25. Liu CL, Ye P, Lin J, Miao CH. L2/IL2 mAb complexes induce in vivo expansion of Treg cells and prevent anti-FVIII antibody production following FVIII protein replacement therapy in hemophilia A mice. Blood (2011) 118(21):23. doi:10.1038/mt.2011.61
26. Hausl C, Ahmad RU, Schwarz HP, Muchitsch EM, Turecek PL, Dorner F, et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood (2004) 104(1):115-22. doi:10.1182/blood-2003-07-2456
27. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol (2011) 7(3):170-8. doi:10.1038/nrrheum.2011.1
28. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 6(10):741-50. doi:10.1038/nri1886
29. Meslier Y, André S, Dimitrov JD, Delignat S, Bayry J, Kaveri SV, et al. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. J Thromb Haemost (2011) 9(4):719-28. doi:10.1111/j.1538-7836.2011.04200.x
30. Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia (2005) 11(1):13-9. doi:10.1111/j.1365-2516.2005.01060.x
31. Biss TT, Velangi MR, Hanley JP. Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature. Haemophilia (2006) 12(3):280-4. doi:10.1111/j.1365-2516.2006.01212.x
32. Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia (2006) 12(1):7-18. doi:10.1111/j.1365-2516.2005.01170.x
33. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia (2006) 12(3):218-22. doi:10.1111/j.1365-2516.2006.01215.x
34. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs (2006) 66(15):1933-48. doi:10.2165/00003495-200666150-00004
35. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 32(1):129-40. doi:10.1016/j.immuni.2009.11.009
36. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol (2007) 178(12):7868-78.
37. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res (1995) 1:53-71. doi:10.1007/978-1-4615-1809-9_5
38. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 162(5):2775-84.
39. Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood (2003) 101(7):2886-93. doi:10.1182/blood-2002-10-3014
40. 4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 178(11):7018-31.
41. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, Martino G, et al. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol (2010) 220(1-2):52-63. doi:10.1016/j.jneuroim.2010.01.001
42. Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost (2011) 9(8):1524-33. doi:10.1111/j.1538-7836.2011.04351.x
43. Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, Price SD, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther (2012) 20(7):1410-6. doi:10.1038/mt.2012.84
44. McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 121(17):3335-44. doi:10.1182/blood-2012-10-462200
45. Zhong L, Jayandharan GR, Aslanidi GV, Zolotukhin S, Herzog RW, Srivastava A. Development of novel recombinant AAV vectors and strategies for the potential gene therapy of hemophilia. J Genet Syndr Gene Ther (2012) S1:008. doi:10.4172/2157-7412.S1-008
46. Markusic DM, Herzog RW. Liver-directed adeno-associated viral gene therapy for hemophilia. J Genet Syndr Gene Ther (2012) 1:1-9. doi:10.4172/2157-7412.S1-009
47. Mátrai J, Cantore A, Bartholomae CC, Annoni A, Wang W, Acosta-Sanchez A, et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology (2011) 53(5):1696-707. doi:10.1002/hep.24230
48. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood (1996) 88(9):3446-50.
49. Miao CH, Ye X, Thompson AR. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther (2003) 14(14):1297-305. doi:10.1089/104303403322319381
50. Ye P, Thompson AR, Sarkar R, Shen Z, Lillicrap DP, Kaufman RJ, et al. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther (2004) 10(1):117-26. doi:10.1016/j.ymthe.2004.04.009
51. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh (1975) 34(2):612.